Popular
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
CardiologyHypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
CardiologyHypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
"You don't have to know programming to create solutions," says Dr. Michal Nedoszytko, Creator of PostVisit.ai
The Convergence"You don't have to know programming to create solutions," says Dr. Michal Nedoszytko, Creator of PostVisit.ai
ESTI Refines Pulmonary Nodule Management in Lung Cancer Screening
Project Oncology®ESTI Refines Pulmonary Nodule Management in Lung Cancer Screening
Concurrent Atezolizumab Fails to Improve Survival in Limited-Stage SCLC
Project Oncology®Concurrent Atezolizumab Fails to Improve Survival in Limited-Stage SCLC
Programs
"We have tools that can think alongside us and free us from a lot of burdens," says Dr. Raja-Elie Abdulnour from NEJM Clinician
The Convergence"We have tools that can think alongside us and free us from a lot of burdens," says Dr. Raja-Elie Abdulnour from NEJM Clinician
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
CardiologyHypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
CardiologySCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Evolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV
CardiologyEvolocumab in Patients Without Significant Atherosclerosis and With Diabetes: A Cardiology Perspective on VESALIUS-CV
Chairperson’s Perspective: Evidence-Informed Clinical Decision-Making in HER2-Overexpressed and TROP2-Targeted NSCLC
CME/CEChairperson’s Perspective: Evidence-Informed Clinical Decision-Making in HER2-Overexpressed and TROP2-Targeted NSCLC
Targeting Epicardial Adipose Tissue in Patients With HFpEF Without Diabetes: Sotagliflozin Effect From SOTA-P-CARDIA Trial Sub-Analysis
CardiologyTargeting Epicardial Adipose Tissue in Patients With HFpEF Without Diabetes: Sotagliflozin Effect From SOTA-P-CARDIA Trial Sub-Analysis
Clinical Practice
Cracking the Code of Obstruction: Unmet Needs in oHCM
MinuteCE®Cracking the Code of Obstruction: Unmet Needs in oHCM
Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
MinuteCE®Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
MinuteCE®Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL
Neuroplasticity: A Potential Target for the Treatment of Depression
Medical Industry FeatureNeuroplasticity: A Potential Target for the Treatment of Depression
Applying Advances in Practice: Case-Based Look at Selecting Therapy for Cushing Syndrome
CME/CEApplying Advances in Practice: Case-Based Look at Selecting Therapy for Cushing Syndrome
Doctors Lounge
Disparities in Osteoporosis Care: Addressing Screening and Treatment Barriers
On the Frontlines of OsteoporosisDisparities in Osteoporosis Care: Addressing Screening and Treatment Barriers
MS Management: Strategies for Ensuring Equitable Access to Teleneurology
On the Frontlines of Multiple SclerosisMS Management: Strategies for Ensuring Equitable Access to Teleneurology
The Changing Landscape of CRC Screening and Prevention
On the Frontlines of Colorectal CancerThe Changing Landscape of CRC Screening and Prevention
"A big revolution is coming in ultrasound," says Dr. Clément Papadacci from Inserm
The Convergence"A big revolution is coming in ultrasound," says Dr. Clément Papadacci from Inserm
"Tom is engaging with all of the patients you aren't seeing today–that's the actual power," says Jean-Claude Saghbini from Lumeris
The Convergence"Tom is engaging with all of the patients you aren't seeing today–that's the actual power," says Jean-Claude Saghbini from Lumeris
Death by Planet? Strange Diagnoses from 1632 London’s Medical Records
Rub Some Dirt In ItDeath by Planet? Strange Diagnoses from 1632 London’s Medical Records
CME
DKA in Focus: What the New Consensus Means for Practice
CME/CEDKA in Focus: What the New Consensus Means for Practice
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
CME/CEStuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
When to Begin FcRn: Initiation Criteria, Key Evidence
MinuteCE®When to Begin FcRn: Initiation Criteria, Key Evidence
Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
CME/CETransforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
Industry Feature
Living with Psoriatic Arthritis: A Doctor-Patient Conversation
Medical Industry FeatureLiving with Psoriatic Arthritis: A Doctor-Patient Conversation
Anti-Amyloid Therapy in Early Alzheimer’s Disease: Real-World Experience and Innovation
Medical Industry FeatureAnti-Amyloid Therapy in Early Alzheimer’s Disease: Real-World Experience and Innovation
Agitation in Alzheimer’s Dementia: From Expert Consensus to Clinical Practice
Medical Industry FeatureAgitation in Alzheimer’s Dementia: From Expert Consensus to Clinical Practice
Targeting Neutrophilic Inflammation in Bronchiectasis: An Emerging Approach
Medical Industry FeatureTargeting Neutrophilic Inflammation in Bronchiectasis: An Emerging Approach
Groundbreaking AI Models Transform Cardiovascular Diagnosis
Medical Industry FeatureGroundbreaking AI Models Transform Cardiovascular Diagnosis
Elevating CV Risk Assessment: Why uACR Deserves a Seat at the Table
Conversations in CV Risk AssessmentElevating CV Risk Assessment: Why uACR Deserves a Seat at the Table